دورية أكاديمية
Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials.
العنوان: | Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials. |
---|---|
المؤلفون: | Gomes MPB; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Linhares JHR; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Dos Santos TP; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Pereira RC; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Santos RT; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., da Silva SA; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Souza MCO; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., da Silva JFA; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Trindade GF; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Gomes VS; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Barreto-Vieira DF; Viral Morphology and Morphogenesis Laboratory, Oswaldo Cruz Institute/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Carvalho MMVF; Immunological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Ano Bom APD; Immunological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Gardinali NR; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Müller R; Pre-Clinical Trials Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Alves NDS; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Moura LDC; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Neves PCDC; Immunological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Esteves GS; Recombinant Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Schwarcz WD; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Missailidis S; Institute of Technology in Immunobiologicals, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Mendes YDS; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., de Lima SMB; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil. |
المصدر: | Viruses [Viruses] 2023 Jun 30; Vol. 15 (7). Date of Electronic Publication: 2023 Jun 30. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
مواضيع طبية MeSH: | SARS-CoV-2* , COVID-19*/prevention & control, Mice ; Animals ; Antibody Formation ; Antibodies, Viral ; Immunization ; Enzyme-Linked Immunosorbent Assay ; Antibodies, Neutralizing |
مستخلص: | Successful SARS-CoV-2 inactivation allows its safe use in Biosafety Level 2 facilities, and the use of the whole viral particle helps in the development of analytical methods and a more reliable immune response, contributing to the development and improvement of in vitro and in vivo assays. In order to obtain a functional product, we evaluated several inactivation protocols and observed that 0.03% beta-propiolactone for 24 h was the best condition tested, as it promoted SARS-CoV-2 inactivation above 99.99% and no cytopathic effect was visualized after five serial passages. Moreover, RT-qPCR and transmission electron microscopy revealed that RNA quantification and viral structure integrity were preserved. The antigenicity of inactivated SARS-CoV-2 was confirmed by ELISA using different Spike-neutralizing monoclonal antibodies. K18-hACE2 mice immunized with inactivated SARS-CoV-2, formulated in AddaS0 |
References: | J Clin Microbiol. 1986 Oct;24(4):527-31. (PMID: 3021808) PLoS One. 2021 Sep 15;16(9):e0256813. (PMID: 34525109) Viruses. 2023 Feb 09;15(2):. (PMID: 36851694) Science. 2020 Jul 3;369(6499):77-81. (PMID: 32376603) Microsc Res Tech. 2022 Feb;85(2):562-569. (PMID: 34498784) Viruses. 2021 Mar 26;13(4):. (PMID: 33810401) Lancet Infect Dis. 2021 Jan;21(1):39-51. (PMID: 33069281) Appl Environ Microbiol. 1997 Aug;63(8):3199-204. (PMID: 9251206) Methods Mol Biol. 2022;2409:11-30. (PMID: 34709632) J Clin Lab Anal. 2021 Apr;35(4):e23735. (PMID: 33608968) Methods Mol Biol. 2009;510:329-36. (PMID: 19009272) Histochem J. 1975 May;7(3):267-76. (PMID: 805108) Pathogens. 2022 Feb 19;11(2):. (PMID: 35215213) Vaccines (Basel). 2021 Nov 02;9(11):. (PMID: 34835197) Clin Rev Allergy Immunol. 2005 Dec;29(3):333-44. (PMID: 16391410) Vaccines (Basel). 2021 Mar 03;9(3):. (PMID: 33802467) J Virol Methods. 2021 Apr;290:114087. (PMID: 33515663) Nat Commun. 2021 Mar 2;12(1):1386. (PMID: 33654090) J Virol Methods. 1987 May;16(1-2):21-8. (PMID: 3038939) Viruses. 2022 Aug 31;14(9):. (PMID: 36146745) J Gen Microbiol. 1964 Apr;35:75-80. (PMID: 14171261) Vaccine. 2015 Aug 20;33(35):4261-8. (PMID: 25862300) Virol Sin. 2021 Oct;36(5):879-889. (PMID: 33835391) Virus Res. 2021 Nov;305:198555. (PMID: 34487766) Lancet Infect Dis. 2021 May;21(5):637-646. (PMID: 33485468) Expert Rev Vaccines. 2012 Jun;11(6):695-719. (PMID: 22873127) Viruses. 2020 Jun 06;12(6):. (PMID: 32517266) J Infect Dis. 2020 Oct 1;222(9):1462-1467. (PMID: 32798217) iScience. 2021 Apr 23;24(4):102298. (PMID: 33723528) Artif Cells Nanomed Biotechnol. 2018 Feb;46(1):33-38. (PMID: 29081252) Appl Environ Microbiol. 2021 Sep 10;87(19):e0031421. (PMID: 34288702) Emerg Microbes Infect. 2020 Dec;9(1):2606-2618. (PMID: 33241728) Curr Opin Virol. 2012 Feb;2(1):84-9. (PMID: 22440970) Mol Immunol. 2022 Jul;147:199-208. (PMID: 35644072) Viruses. 2022 Aug 30;14(9):. (PMID: 36146723) Viruses. 2020 Jul 07;12(7):. (PMID: 32646015) Int J Infect Dis. 2004 Jan;8(1):21-5. (PMID: 14690777) J Virol Methods. 2004 Oct;121(1):85-91. (PMID: 15350737) |
فهرسة مساهمة: | Keywords: K18-hACE2 transgenic mice; PRNT50; RT-qPCR; SARS-CoV-2 inactivation; TCID50; beta-propiolactone; immune response; non-clinical trials; serial passages |
المشرفين على المادة: | 0 (Antibodies, Viral) 0 (Antibodies, Neutralizing) |
تواريخ الأحداث: | Date Created: 20230729 Date Completed: 20230731 Latest Revision: 20230803 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC10386713 |
DOI: | 10.3390/v15071486 |
PMID: | 37515173 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1999-4915 |
---|---|
DOI: | 10.3390/v15071486 |